Story

Zoetis Stock Rebounds Despite Drastic Cut to 2026 Financial Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Zoetis Stock Rebounds Despite Drastic Cut to 2026 Financial Outlook
Text size
Background

Shares of Zoetis (ZTS) recovered from an intraday low to trade higher on Tuesday, even after the animal health giant significantly lowered its full-year financial guidance due to mounting pressure in the U.S. pet care market. The company's mixed second-quarter earnings report, released before the market open, revealed a slight profit beat but a substantial cut to its 2026 forecast.

A Mixed Report and Slashed Outlook

Zoetis reported second-quarter adjusted earnings per share (EPS) of $1.87, narrowly beating the analyst consensus of $1.86. However, revenue came in flat year-over-year at approximately $2.5 billion, missing estimates.

The more significant development was the sharp downward revision to its full-year 2026 forecast. The company now expects:

  • Adjusted EPS: $6.15 to $6.25, far below the consensus estimate of $6.87.
  • Annual Revenue: $9.12 billion to $9.32 billion, a reduction from its prior range of $9.68 billion to $9.96 billion.

Headwinds in the US Pet Market

Sample IUX Markets – In-articleAd

According to CEO Kristin Peck, the guidance reduction was driven by challenges in the company's largest segment, companion animals. U.S. revenue for this unit declined 7% during the quarter. The company cited fewer visits to veterinary clinics, increased price sensitivity among pet owners, and intensifying competition as the primary factors behind the slowdown.

This domestic weakness was partially offset by stronger performance abroad, with international revenue rising 6%. The company also announced the appointment of Jay Saccaro, formerly of GE HealthCare, as its new Executive Vice President, CFO, and COO, effective August 17.

Market Reaction and Context

Despite the negative outlook, the stock's rebound may reflect investor sentiment that the bad news was already priced in. Shares of Zoetis have fallen by roughly half over the past 12 months and recently touched a 52-week low. After an initial selloff, some investors may be viewing the stock's compressed valuation as an opportunity.

The stock's performance stands in contrast to peer IDEXX Laboratories, which recently raised its own annual profit forecast. Zoetis experienced significant intraday volatility, opening higher before falling to a session low of $73.72 and then climbing into positive territory, highlighting the market's struggle to digest the competing signals of a minor earnings beat against a severe guidance cut.

Read next

More on Stocks
Back to latest news

LATEST